Clinical Trial Update: A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, tolerability, efficacy, and quality of life of human recombinant AP (recAP) in patients with acute kidney injury (SA-AKI) has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Drugs mentioned

• human recombinant alkaline phosphatase (recAP) (human recombinant alkaline phosphatase)

Snippet

Sponsor: AM-Pharma | Conditions: Acute Kidney Injury | Phase 2 | Status: COMPLETED | Results posted: 2020-03-23